Table 2: Grade 1/2 treatment-emergent adverse events occurring in >10% of subjects and Grade 3 TEAEs regardless of frequency.
Listed below are adverse events reported in at least 10% of the patients (n=32) with advanced solid tumors who received STM 434 and that were deemed by the investigators to be related to study drug. No treatment-emergent grade 4 or 5 events were reported.
| Adverse Event, n (%) | Grade 1/2 | Grade 3 | All Grades (n=32) |
|---|---|---|---|
| Fatigue | 13 (41) | 0 | 13 (41) |
| Epistaxis | 10 (31) | 1 (3)1 | 11 (34) |
| Gingival bleeding | 7 (22) | 0 | 7 (22) |
| Headache | 7 (22) | 0 | 7 (22) |
| Peripheral edema | 7 (22) | 0 | 7 (22) |
| Abdominal pain | 4 (13) | 2 (6)2 | 6 (19) |
| Diarrhea | 6 (19) | 0 | 6 (19) |
| Pyrexia | 6 (19) | 0 | 6 (19) |
| Rash, maculo-papular | 6 (19) | 0 | 6 (19) |
| Anemia | 3 (9) | 2 (6)3 | 5 (16) |
| Decreased appetite | 4 (13) | 0 | 4 (13) |
| Dyspnea | 4 (13) | 0 | 4 (13) |
| Nausea | 4 (13) | 0 | 4 (13) |
1
8 mg/kg Q2W cohort
2
0.25 mg/kg Q4W and 0.5 mg/kg Q2W cohorts
3
2.0 mg/kg Q2W cohort